Photoactivated cancer therapeutic methods emerging in
recent decades,
such as photothermal therapy (PTT) and photodynamic therapy (PDT),
have drawn worldwide research interest. Herein, a smart near-infrared
(NIR) photosensitizer 4-(4-(7-(4-Bromophenyl)-1,9-bis(3,4-dimethoxyphenyl)-5,5-difluoro-5H-5l4,6l4-dipyrrolo[1,2-c:2′,1′-f][1,3,5,2]triazaborinin-3-yl)phenyl)morpholine
(MAB) with morpholine decorating on the aza-BODIPY core is synthesized
to achieve dual-modal imaging-guided synergistic PDT/PTT, exhibiting
a tumor microenvironment (TME) enhanced cancer theranostic performance.
The introduction of electron-donating morpholine offers MAB-enhanced
intramolecular charge transfer (ICT) and a pronounced red-shift with
maximum absorption peak (λmax) at 730 nm. After encapsulating
with amphiphilic polymer DSPE-mPEG2000, as-obtained MAB
nanoparticles (NPs) with good biocompatibility can enrich targeting
in the lysosomes of tumor cells and afterward be activated under the
acidic microenvironment inside the lysosome (pH 5.0) to generate intracellular
reactive oxygen species (ROS) for enhanced PDT through interruption
of photoinduced electron transfer (PET). Through in vitro cytotoxicity assay studies, the half-maximal inhibitory concentration
(IC50) of MAB NPs under irradiation with the 730 nm laser
is ∼10 μg/mL, indicating an excellent phototherapy effect.
Furthermore, an in vivo study illustrates a prominent
PDT/PTT synergistic therapeutic effect, and MAB NPs can be rapidly
metabolized.